Efficacy of PP121 in primary and metastatic non‑small cell lung cancers

Quick,Quincy A.

doi:10.3892/br.2023.1611

Efficacy of PP121 in primary and metastatic non‑small cell lung cancers

Authors:
- Quincy A. Quick
View Affiliations

Affiliations: Department of Biological Sciences, Tennessee State University, Nashville, TN 37209, USA
Published online on: March 1, 2023 https://doi.org/10.3892/br.2023.1611
Article Number: 29
Copyright: © Quick . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tyrosine kinase inhibitors are a clinically standard treatment option for non‑small cell lung cancers (NSCLCs), the leading cause of cancer‑related deaths in the US. These targeted agents include first, second and third generation tyrosine kinase inhibitors; however, these lack clinical efficacy in the treatment of NSCLC due to intrinsic and acquired resistance. This resistance may be a result of genetic aberrations in oncogenic signaling mediators of divergent pathways. The present study aimed to investigate a novel dual tyrosine kinase and PI3K inhibitor, PP121, as a targeted agent in NSCLC cell lines. The present study co‑cultured PP121 with healthy human astrocytes, a prevalent cell type located in the brain of NSCLC brain metastases. To date, few preclinical studies have examined the efficacy of PP121 as an anticancer agent, and to the best of my knowledge, no previous studies have previously evaluated its therapeutic potential in the treatment of NSCLC. To investigate the clinical heterogeneity of NSCLC, patient‑derived adenocarcinoma (ADC) and squamous cell carcinoma (SCC) xenograft models were used, which exhibited epidermal growth factor receptor (EGFR) mutations and mesenchymal‑epithelial transition (MET) factor amplifications. Notably, both EGFR and MET are known contributors to tyrosine kinase inhibitor resistance; thus, the aforementioned mutations and amplifications enabled the effects of PP121 to be evaluated in these solid tumors. In addition, a co‑cultured model system using both NSCLC cells and astrocytes was employed to assess the effects of PP121 on the invasion of ADC and SCC cells in a multicellular environment. Results of the present study demonstrated that PP121 exerted an antitumorigenic effect in the aforementioned model systems via downregulation of pharmacodynamic targets.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012.PubMed/NCBI View Article : Google Scholar
2	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013.PubMed/NCBI View Article : Google Scholar
3	Yuan M, Huang LL, Chen JH, Wu J and Xu Q: The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Sig Transduct Target Ther. 4(61)2019.PubMed/NCBI View Article : Google Scholar
4	König D, Savic Prince S and Rothschild SI: Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations. Cancers (Basel). 13(804)2021.PubMed/NCBI View Article : Google Scholar
5	Gazdar AF: Activating and resistance mutations of EGFR in non-small-cell lung cancer: Role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene. 28 (Suppl 1):S24–S31. 2009.PubMed/NCBI View Article : Google Scholar
6	Clark J, Cools J and Gilliland DG: EGFR inhibition in non-small cell lung cancer: Resistance, once again, rears its ugly head. PLoS Med. 2(e75)2005.PubMed/NCBI View Article : Google Scholar
7	Suda K, Murakami I, Katayama T, Tomizawa K, Osada H, Sekido Y, Maehara Y, Yatabe Y and Mitsudomi T: Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin Cancer Res. 16:5489–5498. 2010.PubMed/NCBI View Article : Google Scholar
8	Li F, Zhu T, Cao B, Wang J and Liang L: Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance. Eur J Cancer. 84:184–192. 2017.PubMed/NCBI View Article : Google Scholar
9	Zhang Z, Zhang Y, Luo F, Ma Y, Fang W, Zhan J, Li S, Yang Y, Zhao Y, Hong S, et al: Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer. Clin Transl Med. 10(e33)2020.PubMed/NCBI View Article : Google Scholar
10	Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, Vena N, Bailey D, Yeap BY, Fiorentino M, et al: Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol. 177:415–423. 2010.PubMed/NCBI View Article : Google Scholar
11	Preusser M, Streubel B, Berghoff AS, Hainfellner JA, von Deimling A, Widhalm G, Dieckmann K, Wöhrer A, Hackl M, Zielinski C and Birner P: Amplification and overexpression of CMET is a common event in brain metastases of non-small cell lung cancer. Histopathology. 65:684–692. 2014.PubMed/NCBI View Article : Google Scholar
12	Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX and Stern DF: EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 73:5053–5065. 2013.PubMed/NCBI View Article : Google Scholar
13	Peng Y, Zhou Y, Cheng L, Hu D, Zhou X, Wang Z, Xie C and Zhou F: The anti-esophageal cancer cell activity by a novel tyrosine/phosphoinositide kinase inhibitor PP121. Biochem Biophys Res Commun. 465:137–144. 2015.PubMed/NCBI View Article : Google Scholar
14	Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM and Knight ZA: Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 4:691–699. 2008.PubMed/NCBI View Article : Google Scholar
15	Che HY, Guo HY, Si XW, You QY and Lou WY: PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration. Tumour Biol. 35:8659–8664. 2014.PubMed/NCBI View Article : Google Scholar
16	Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, et al: Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis. Mol Cancer Ther. 19:52–62. 2020.PubMed/NCBI View Article : Google Scholar
17	Moore G, Lightner C, Elbai S, Brady L, Nicholson S, Ryan R, O'Sullivan KE, O'Byrne KJ, Blanco-Aparicio C, Cuffe S, et al: Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. Cancers (Basel). 13(2139)2021.PubMed/NCBI View Article : Google Scholar
18	Montaudon E, El Botty R, Vacher S, Déas O, Naguez A, Chateau-Joubert S, Treguer D, de Plater L, Zemoura L, Némati F, et al: High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC. Oncotarget. 12:859–872. 2021.PubMed/NCBI View Article : Google Scholar
19	Han J, Liu Y, Yang S, Wu X, Li H and Wang Q: MEK inhibitors for the treatment of non-small cell lung cancer. J Hematol Oncol. 14(1)2021.PubMed/NCBI View Article : Google Scholar
20	Pérez-Tomás R: Multidrug resistance: Retrospect and prospects in anti-cancer drug treatment. Curr Med Chem. 13:1859–1876. 2006.PubMed/NCBI View Article : Google Scholar
21	Chen KG, Valencia JC, Gillet JP, Hearing VJ and Gottesman MM: Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma. Pigment Cell Melanoma Res. 22:740–749. 2009.PubMed/NCBI View Article : Google Scholar
22	Chai AB, Callaghan R and Gelissen IC: Regulation of P-Glycoprotein in the Brain. Int J Mol Sci. 23(14667)2022.PubMed/NCBI View Article : Google Scholar
23	Haar CP, Hebbar P, Wallace GC IV, Das A, Vandergrift WA III, Smith JA, Giglio P, Patel SJ, Ray SK and Banik NL: Drug resistance in glioblastoma: A mini review. Neurochem Res. 37:1192–1200. 2012.PubMed/NCBI View Article : Google Scholar
24	Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA. 104:20932–20937. 2007.PubMed/NCBI View Article : Google Scholar
25	Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z, Cheng Y, He J, Shi Y, Zhao Y, et al: Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial. JAMA Oncol. 4:1569–1575. 2018.PubMed/NCBI View Article : Google Scholar
26	Zhang M, Quan H, Fu L, Li Y, Fu H and Lou L: Third-generation EGFR inhibitor HS-10296 in combination with famitinib, a multi-targeted tyrosine kinase inhibitor, exerts synergistic antitumor effects through enhanced inhibition of downstream signaling in EGFR-mutant non-small cell lung cancer cells. Thorac Cancer. 12:1210–1218. 2021.PubMed/NCBI View Article : Google Scholar
27	Sun YW, Xu J, Zhou J and Liu WJ: Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget. 9:5459–5472. 2017.PubMed/NCBI View Article : Google Scholar
28	Dai W, Zhu H, Chen G, Gu H, Gu Y, Sun X and Zeng X: Orchestration of the crosstalk between astrocytes and cancer cells affects the treatment and prognosis of lung cancer sufferers with brain metastasis. J Thorac Dis. 8:E1450–E1454. 2016.PubMed/NCBI View Article : Google Scholar
29	Lin J, Jandial R, Nesbit A, Badie B and Chen M: Current and emerging treatments for brain metastases. Oncology (Williston Park). 29:250–257. 2015.PubMed/NCBI
30	Ni W, Chen W and Lu Y: Emerging findings into molecular mechanism of brain metastasis. Cancer Med. 7:3820–3833. 2018.PubMed/NCBI View Article : Google Scholar
31	Hanibuchi M, Kim SJ, Fidler IJ and Nishioka Y: The molecular biology of lung cancer brain metastasis: An overview of current comprehensions and future perspectives. J Med Invest. 61:241–253. 2014.PubMed/NCBI View Article : Google Scholar